Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: A three-center-based study of 38 patients

Gastric Cancer

Volumn 10, Issue 3, 2007, Pages 145-152

  Al Batran, Salah Eddin ^a   Hartmann, Joerg Thomas ^b   Heidel, Florian ^c   Stoehlmacher, Jan ^d   Wardelmann, Eva ^e   Dechow, Claudius ^a   Düx, Markus ^a   Izbicki, Jacob Robert ^d   Kraus, Thomas ^a   Fischer, Thomas ^c   Jäger, Elke ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Focal; Gastrointestinal; Generalized; Imatinib; Limited; Progression; Stromal; Tumor

Indexed keywords

IMATINIB;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; HUMAN; KIT GENE; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35148861056     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-007-0425-8     Document Type: Article

References (18)

1. S George J Desai 2002 Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors Curr Treat Options Oncol 3 489 96
2. S Hirota K Isozaki Y Moriyama K Hashimoto T Nishida S Ishiguro 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 80
3. CL Corless JA Fletcher MC Heinrich 2004 Biology of gastrointestinal stromal tumors J Clin Oncol 22 3813 25
4. CL Corless A Schroeder D Griffith A Town L McGreevey P Harrell 2005 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib J Clin Oncol 23 5357 64
5. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 80
6. RP Dematteo MC Heinrich WM El-Rifai G Demetri 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466 77
7. LL Chen JC Trent EF Wu GN Fuller L Ramdas W Zhang 2004 A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors Cancer Res 64 913 9
8. JY Blay S Bonvalot P Casali H Choi M Debiec-Richter AP Dei Tos 2005 Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO Ann Oncol 16 566 78
9. E Wardelmann A Hrychyk S Merkelbach-Bruse K Pauls J Goldstein P Hohenberger 2004 Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors J Mol Diagn 6 197 204
10. M Van Glabbeke J Verweij PG Casali A Le Cesne P Hohenberger I Ray-Coquard 2005 Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study J Clin Oncol 23 5795 804
11. CR Antonescu P Besmer T Guo K Arkun G Hom B Koryotowski 2005 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182 90
12. CP Raut M Posner J Desai JA Morgan S George D Zahrieh 2006 Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2325 31
13. AT Van Oosterom I Judson J Verweij S Stroobants E Donato di Paola European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 1421 3
14. J Verweij PG Casali J Zalcberg A LeCesne P Reichardt JY Blay 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 34
15. JR Zalcberg J Verweij PG Casali A Le Cesne P Reichardt JY Blay 2005 Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800∈mg after progression on 400∈mg Eur J Cancer 1 1751 7
16. E Tamborini L Bonadiman A Greco V Albertini T Negri A Gronchi 2004 A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 294 9
17. E Tamborini E Gabanti MS Lagonigro T Negri S Pilotti MA Pierotti 2005 KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient Cancer Res 65 1115
18. E Wardelmann N Thomas S Merkelbach-Bruse K Pauls N Speidel 2005 Acquired resistance to imatinib in gastrointestinal stromal tumors caused by multiple KIT mutations Lancet Oncol 6 249 51